AlzeCure Pharma (ALZCUR) Q2 2024 earnings summary

Executive summary

• AlzeCure develops innovative small-molecule drugs for CNS diseases, focusing on Alzheimer's and pain, with multiple candidates in clinical and preclinical phases across three platforms: NeuroRestore, Alzstatin, and Painless.

• Q2 2024 saw significant R&D progress, new preclinical and clinical data, a successful rights issue raising SEK 39.2 million, and the addition of Dr. Jan Lundberg to the Board.

• The company is preparing for Phase II trials for ACD856 (Alzheimer's) and ACD440 (neuropathic pain), while advancing Alzstatin and TrkA-NAM projects.

Financial highlights

• Net sales were SEK 0 thousand for both Q2 and H1 2024, unchanged from the previous year.

• Q2 2024 loss was SEK -8,653 thousand, an improvement from SEK -10,211 thousand in Q2 2023; H1 2024 loss was SEK -18,457 thousand, compared to SEK -19,756 thousand year-over-year.

• Earnings per share, basic, were SEK -0.12 for Q2 2024 (vs. -0.16) and SEK -0.28 for H1 2024 (vs. -0.32).

• Cash and cash equivalents at period end were SEK 43,916 thousand, down from SEK 45,232 thousand a year earlier.

• Research expenses accounted for 66.0% of operating expenses in Q2 2024 and 68.2% for H1 2024.

Outlook and guidance

• The company will focus on advancing Alzstatin candidates and TrkA-NAM toward clinical trials, and prepare Phase II trials for ACD856 and ACD440.

• Business development efforts continue, aiming for out-licensing or partnerships for at least one project.

• Financing risk remains high; available funds are not sufficient for all planned activities over the next 12 months, and further capital may be required.